Connor Clark & Lunn Investment Management Ltd. Invests $6.93 Million in Aurinia Pharmaceuticals Inc $AUPH

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 408,453 shares of the biotechnology company’s stock, valued at approximately $6,931,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.31% of Aurinia Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. BOK Financial Private Wealth Inc. bought a new stake in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $32,000. Global Retirement Partners LLC bought a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $41,000. Quantbot Technologies LP bought a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth approximately $45,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Aurinia Pharmaceuticals in the third quarter valued at approximately $48,000. Finally, Frazier Financial Advisors LLC raised its holdings in shares of Aurinia Pharmaceuticals by 411.9% in the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 2,793 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

NASDAQ:AUPH opened at $16.54 on Thursday. Aurinia Pharmaceuticals Inc has a one year low of $10.34 and a one year high of $19.25. The company has a market cap of $2.20 billion, a P/E ratio of 7.22 and a beta of 1.42. The firm’s fifty day moving average price is $15.98 and its two-hundred day moving average price is $15.47. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.42 and a quick ratio of 4.97.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04. The firm had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. Equities analysts expect that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang purchased 343,620 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were acquired at an average cost of $15.28 per share, with a total value of $5,250,513.60. Following the completion of the transaction, the chief executive officer owned 12,838,101 shares in the company, valued at $196,166,183.28. The trade was a 2.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought 814,606 shares of company stock valued at $12,455,129 in the last 90 days. Corporate insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Royal Bank Of Canada lifted their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Friday, August 7th. Zacks Research cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $17.67.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.